Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Cells

The fight against osteoarthritis (OA) is on at the Kennedy Institute’s Centre for Osteoarthritis Pathogenesis. We have been awarded two research grants looking at different aspects of OA with the ultimate aim of developing novel treatments for this painful and disabling condition.

OA is the most common type of arthritis in the UK, causing the joints to progressively become painful and stiff and making everyday tasks very difficult for patients. When a joint develops osteoarthritis, the cartilage on the end of the bone gradually roughens and becomes thin, whilst the bone underneath thickens.

Osteoarthritis is also the biggest healthcare challenge in rheumatology as there are no effective treatments available; patients rely on painkillers and eventually joint replacement surgery.  

Professor Tonia Vincent, lead researcher for both projects says of the awards: “These two projects are deeply embedded within our OAPathogenesis Centre and will help to stratify patients for future clinical trials and to identify novel therapeutic targets’”

Cartilage repair.

In collaboration with researchers at Utrecht University, this innovative study will look to validate novel markers of cartilage repair in OA patients, paving the way for a potential powerful, cheap, and acceptable treatment for many with advanced OA.

New evidence suggests that osteoarthritic cartilage is able to repair itself if the adverse mechanical environment of the joint is corrected; this has a significant and sustained improvement in pain, but also on cartilage ‘re-growth’. Researchers have identified molecules – biomarkers – that are activated following joint injury and likely drive repair responses, in mouse models. Identifying these biomarkers of successful repair in OA patients has the potential to change the way we view disease, empower patients into believing that their disease is modifiable and open up new possibilities for cheaper, globally applicable treatments.

Project title: Identifying markers in the synovial fluid of patients with osteoarthritis (OA) that predict their ability to repair cartilage
Funder: Arthritis Research UK Project Grant

 

Novel non-invasive imaging method.

The team at the Kennedy Institute, led by Professor Tonia Vincent and Dr Ngee Han Lim, will work to develop a novel imaging agent that can be combined with microCT scanning to create a sensitive, quantitative cartilage assessment tool in OA.

Investigating the pathways that cause OA has been very challenging as the human condition is very variable in its course, it is difficult to obtain tissues from patients and we currently have no way of detecting early disease. In this context, animal models of OA have significant utility because disease can be studied at all stages of the condition, tissues are readily available, and the onset of disease is known.

Evaluation of joint damage both in clinic and in animal models of OA is hampered by the inability to image cartilage accurately and non-invasively. A non-invasive imaging method that would be able to visualise the degradation of cartilage over time would greatly reduce the numbers of animals being used in arthritis research, as well as being potentially translatable into a clinical imaging agent for early OA in humans.

Project title: Development of novel imaging agents for the prospective quantification of joint damage to reduce animal numbers is osteoarthritis research
Funder: NC3Rs – National Centre for the Replacement, Refinement & Reduction of Animals in Research

Similar stories

Could patients with common fractures recover without routine hospital follow-up?

The FASTER study will investigate whether thousands of people with common fractures can recover just as well with good-quality advice and rehabilitation guidance, without the need for routine hospital follow-up appointments.

Could the gut’s nervous system hold new clues to treating Crohn’s disease?

Researchers at the Kennedy Institute are investigating whether the nervous system within the gut could provide a new way to understand and ultimately treat Crohn’s disease.

NDORMS appoints a new Research Professor of Regulatory Innovation to help accelerate the development pipeline of new treatments

Lincoln Tsang has been appointed as the new John Climax Research Professor of Regulatory Innovation – a new role at NDORMS and the University of Oxford that brings global regulatory and legal expertise to our ambitions to transform and improve drug development pathways in order to help deliver safe and effective treatments to patients sooner. He will assume this role effective 2 January 2027.

Look Beyond My Skin: Your Psoriasis Could Help Us Understand Who Develops Psoriatic Arthritis

Adults with psoriasis across Europe are invited to take part in an online study aiming to identify who is at risk of developing psoriatic arthritis.

New PI Marie Pust aims to bring microbiome research closer to patients

We welcome Marie-Madlen Pust, who has joined the Kennedy Institute as a new Principal Investigator. Marie will establish a research group combining computational biology with targeted experimental microbiology to identify microbial drivers of chronic inflammatory disease that can be monitored (diagnostic potential) or modified (therapeutic potential).

Oxford EMCRF starts pioneering engineered nTreg trial for severe autoimmune disease

The Oxford Experimental Medicine Clinical Research Facility (EMCRF) has recruited its first patients into the CHILL trial, an early-phase study of an innovative cell therapy for severe autoimmune disease.